|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
Statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Tannock IF, Osoba D, Stockler MR, et al:
Chemotherapy with mitoxantrone plus prednisone or prednisone alone
for symptomatic hormone-resistant prostate cancer: a Canadian
randomized trial with palliative end points. J Clin Oncol.
14:1756–1764. 1996.
|
|
3
|
Tannock IF, Wit R, Berry WR, et al:
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qi WX, Shen Z and Yao Y: Docetaxel-based
therapy with or without estramustine as first-line chemotherapy for
castration-resistant prostate cancer: a meta-analysis of four
randomized controlled trials. J Cancer Res Clin Oncol.
137:1785–1790. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jadad AR, Moore RA, Carroll D, et al:
Assessing the quality of reports of randomized clinical trials: Is
blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar
|
|
6
|
Kelly WK, Halabi S, Carducci M, et al:
Randomized, double-blind, placebo-controlled phase III trial
comparing docetaxel and prednisone with or without bevacizumab in
men with metastatic castration-resistant prostate cancer: CALGB
90401. J Clin Oncol. 30:1534–1540. 2012. View Article : Google Scholar
|
|
7
|
Tannock IF, Fizazi K, Ivanov S, et al:
Aflibercept versus placebo in combination with docetaxel and
prednisone for treatment of men with metastatic
castration-resistant prostate cancer (VENICE): a phase 3,
double-blind randomised trial. Lancet Oncol. 14:760–768. 2013.
View Article : Google Scholar
|
|
8
|
Mathew P, Thall PF, Bucana CD, et al:
Platelet-derived growth factor receptor inhibition and chemotherapy
for castration-resistant prostate cancer with bone metastases. Clin
Cancer Res. 13:5816–5824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Horti J, Widmark A, Stenzl A, et al: A
randomized, double-blind, placebo-controlled phase II study of
vandetanib plus docetaxel/prednisolone in patients with
hormone-refractory prostate cancer. Cancer Biother Radiopharm.
24:175–180. 2009. View Article : Google Scholar
|
|
10
|
Fizazi KS, Higano CS, Nelson JB, et al:
Phase III, randomized, placebo-controlled study of docetaxel in
combination with zibotentan in patients with metastatic
castration-resistant prostate cancer. J Clin Oncol. 31:1740–1747.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Quinn DI, Tangen CM, Hussain M, et al:
Docetaxel and atrasentan versus docetaxel and placebo for men with
advanced castration-resistant prostate cancer (SWOG S0421): a
randomised phase 3 trial. Lancet Oncol. 14:893–900. 2013.
View Article : Google Scholar
|
|
12
|
Dreicer R, Garcia J, Rini B, et al: A
randomized, double-blind, placebo-controlled, phase II study with
and without enzastaurin in combination with docetaxel-based
chemotherapy in patients with castration-resistant metastatic
prostate cancer. Invest New Drugs. 31:1044–1050. 2013. View Article : Google Scholar
|
|
13
|
Pili R, Rosenthal MA, Mainwaring PN, et
al: Phase II study on the addition of ASA404 (vadimezan;
5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin
Cancer Res. 16:2906–2914. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heidenreich A, Rawal SK, Szkarlat K, et
al: A randomized, double-blind, multicenter, phase 2 study of a
human monoclonal antibody to human αv integrins (intetumumab) in
combination with docetaxel and prednisone for the first-line
treatment of patients with metastatic castration-resistant prostate
cancer. Ann Oncol. 24:329–336. 2013.
|
|
15
|
Heath EI, Mannuel HD, Liu G, et al:
Randomized phase II trial of docetaxel (Doc) and prednisone (Pred)
with or without AZD2171 (cediranib), in chemotherapy-naive,
metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451). J
Clin Oncol. 31:(Suppl 6; abstr 38). 2013.
|
|
16
|
Wiechno PJ, Chlosta P, Pikiel J, et al:
Randomized phase II study with window-design to evaluate anti-tumor
activity of the survivin antisense oligonucleotide (ASO) ly2181308
in combination with docetaxel for first-line treatment of
castrate-resistant prostate cancer (CRPC). J Clin Oncol. 31:(Suppl;
abstr 5019). 2013.
|
|
17
|
Sternberg CN, Dumez H, Poppel HV, et al:
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide):
an EORTC multicenter, randomized phase II study in patients with
castration-resistant prostate cancer. Ann Oncol. 20:1264–1269.
2009. View Article : Google Scholar
|
|
18
|
Chi KN, Hotte SJ, Yu EY, et al: Randomized
phase II study of docetaxel and prednisone with or without OGX-011
in patients with metastatic castration-resistant prostate cancer. J
Clin Oncol. 28:4247–4254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dahut WL, Gulley JL, Arlen PM, et al:
Randomized phase II trial of docetaxel plus thalidomide in
androgen-independent prostate cancer. J Clin Oncol. 22:2532–2539.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sonpavde G, Matveev V, Burke JM, et al:
Randomized phase II trial of docetaxel plus prednisone in
combination with placebo or AT-101, an oral small molecule Bcl-2
family antagonist, as first-line therapy for metastatic
castration-resistant prostate cancer. Ann Oncol. 23:1803–1808.
2012. View Article : Google Scholar
|
|
21
|
Berthold DR, Pond GR, Soban F, Wit R,
Eisenberger M and Tannock IF: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer: updated
survival in the TAX 327 study. J Clin Oncol. 26:242–245. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kellokumpu-Lehtinen PL, Harmenberg U,
Joensuu T, et al: 2-weekly versus 3-weekly docetaxel to treat
castration-resistant advanced prostate cancer: a randomised, phase
3 trial. Lancet Oncol. 14:117–124. 2013. View Article : Google Scholar
|
